Biotechnology

Found 39,728 articles

• NKGen Announces Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/25/2023

  NKGen Biotech Inc. (“NKGen”) today announced an upcoming poster presentation by its parent company, NKMax Co., Ltd., on preclinical and clinical data from a Phase I/IIa study of SNK01 in combination with cytotoxic chemotherapy in non-small cell lung cancer, at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held at the McCormick Place Convention Center in Chicago, Illinois from June 2-6, 2023.

• 

  Update: FDA Delays Decision on Sarepta’s DMD Gene Therapy

  5/24/2023

  The FDA set a new action date of June 22 for Sarepta’s gene therapy for the neuromuscular disease, approximately three weeks after the original date of May 29. 
• 

  Wave’s Antisense ALS Therapy Is Company’s Latest Miss

  5/24/2023

  Wave will discontinue development of WVE-004 in C9-associated ALS and frontotemporal dementia after the therapy failed to show any clinical benefit in a mid-stage trial.
• 

  Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function

  5/24/2023

  Researchers elucidate the component structure of Alzheimer’s-associated plaques, shedding light on anti-amyloid antibodies’ mechanism of action.
• 

  Moving From the Bench to Management: How to Become an Effective Leader

  5/24/2023

  Here are some of the skills and tools life science researchers and scientists can use to become successful managers.

• Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

  5/24/2023

  Immutep Limited today announces new encouraging clinical data in 1st line non-small cell lung cancer from INSIGHT-003, an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer Research IKF.

• NeuBase to Participate in Jefferies 2023 Healthcare Conference

  5/24/2023

  NeuBase Therapeutics, Inc. announced that the Company’s management will participate in the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on June 7-9, 2023.

• Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

  5/24/2023

  Pliant Therapeutics, Inc. today announced that it presented Phase 2a clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2023 International Conference, held from May 19 through May 24, 2023.

• TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion

  5/24/2023

  TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the expansion of its mRNA manufacturing capabilities to serve late-phase drug developers.

• Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

  5/24/2023

  Ocugen, Inc. today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen.

• Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug

  5/24/2023

  Enveric Biosciences, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series.

• Lassen Therapeutics Presents Phase I Data on LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting

  5/24/2023

  Lassen Therapeutics presented new preclinical and Phase I data of LASN01 for treatment of pulmonary fibrosis, at today’s American Thoracic Society (ATS) Annual Meeting being held in Washington DC.

• Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

  5/24/2023

  Dermata Therapeutics, Inc. today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 800,877 shares of its common stock.

• Curative Biotechnology, Inc. Files Patent on Ophthalmic Formulation

  5/24/2023

  Curative Biotechnology Inc. announced that a Patent Cooperation Treaty application was duly filed in the U.S. Receiving Office on May 22, 2023, claiming priority to U.S. Provisional Application No. 63/345,759, filed May 25, 2022.

• Be The Match BioTherapies® To Provide Robust Cell Therapy Infrastructure to Support Garuda Therapeutics’ Potentially Ground-Breaking Off-The-Shelf Cell Therapies

  5/24/2023

  Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, announced a working partnership with Garuda Therapeutics, a company working to create off-the-shelf, durable blood stem cell-based cellular therapies.

• Kytopen Reveals Automated High-Throughput Gene Editing Platform to Accelerate Cell Therapy Discovery, Development, and Manufacturing

  5/24/2023

  Kytopen announced the initiation of an early access program for the Flowfect Discover™, an innovative gene delivery platform to engineer cells with unparalleled precision and efficiency.

• Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)

  5/24/2023

  Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial.

• Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital

  5/24/2023

  Tryp Therapeutics, Inc. announced it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome at Massachusetts General Hospital.

• Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 24, 2023

  5/24/2023

  Gritstone bio, Inc. announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 31,000 shares of its common stock with an exercise price of $1.96, which is equal to the closing price of Gritstone’s common stock on May 16, 2023, the date of the grant.

• ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth

  5/24/2023

  ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors.